DispatchHealth clinicians will have access to near real-time insights to optimize patient outcomes and clinical operationsSAN FRANCISCO, Nov. 02, 2022…
ALA-002 is PharmAla’s lead drug candidate, showing exceptional safety and efficacy in preclinical rodent modelsVANCOUVER, British Columbia, Nov. 02, 2022…
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 02, 2022 (GLOBE…
NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage…
TORONTO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) will…
SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments…
– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On…
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development…
Device expands ProSomnus’ suite of FDA-cleared Precision Oral Appliance Therapy Devices for treatment of Obstructive Sleep Apnea (OSA) Device is engineered…
BERKELEY HEIGHTS, N.J. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing…